1. Scrip
  3. >>Anticancer
  4. >>Immuno-oncology

Roche's IMpower130 Met Co-Primary Endpoints, Lifting ASCO Suspense

 
• By Sten Stovall

Roche said its Phase III IMpower130 study met its co-primary endpoints of overall survival and progression-free survival in the advanced first-line setting for non-squamous lung cancer.

Doctor examining at lungs radiograph x-ray film of patient in operation room. medical concept.
Roche Says Tecentriq In IMpower130 Met OS and PFS Co-Primary Endpoints • Source: Shutterstock

Hoping to further support Tecentriq (atezolizumab) in lung cancer, Roche said its Phase III IMpower130 combo study met its co-primary endpoints of overall survival and progression-free survival, and that the anti-PD-L1 MAb plus chemotherapy helped people with metastaticnon-squamous non-small cell lung cancer (NSCLC) live "significantly longer" compared to chemotherapy alone.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immuno-oncology

Arbele Leverages Rights As It Drugs Proprietary CDH17 Target

 
• By Dexter Jie Yan

Arbele has emerged as a global leader in the Cadherin 17 area, not only in clinical progress but also for its “secret recipe” for application in T-cell engagers, its CEO tells Scrip.

Gilead Set To Expand Trodelvy/Keytruda Into Frontline TNBC

 
• By Alaric DeArment

The company reported positive topline results for ASCENT-04, which also bode well for the ASCENT-03 trial in patients with low PD-L1 expression.

In Brief: BriaCell’s Breast Cancer Cell Therapy Boosts Survival In Phase II

 
• By Sushmita Panda

BriaCell announced its cell therapy Bria-IMT plus checkpoint inhibitors bested Gilead’s Trodelvy in a Phase II trial in HR+ breast cancer; a Phase III trial is enrolling.

Scancell Signs UK Match-Making Pact For Melanoma Vaccine

 
• By Kevin Grogan

The Oxford group has linked up with the NHS Cancer Vaccine Launch Pad.

More from Anticancer

Telix Moves TLX101 Forward On Encouraging Early Brain Cancer Data

 
• By Alaric DeArment

The company is planning to start a registrational program on its home turf in Australia and is planning to bring the therapy to the US as well.

Amgen’s Imdelltra Sets The Pace In Small-Cell Lung Cancer

 
• By Andrew McConaghie

The bispecific is the first in its class to record a Phase III survival win in small-cell lung cancer, although antibody-drug conjugates and other rivals could challenge in the coming years.

Scancell Signs UK Match-Making Pact For Melanoma Vaccine

 
• By Kevin Grogan

The Oxford group has linked up with the NHS Cancer Vaccine Launch Pad.